How infections and autoimmune dysfunction can trigger neuropsychiatric symptoms
Autoimmune Brain Panel™
Autoantibody testing for neuropsychiatric disorders
Patients with infection-triggered autoimmune neuropsychiatric disorders are often misdiagnosed with a primary neurologic or psychiatric illness, when they, in fact, have a treatable autoimmune condition.
Infections disrupt immune system and impact the brain
Common infections (i.e., strep, mycoplasma pneumonia and coxsackie virus) can trigger the immune system to produce autoantibodies to destroy the harmful pathogens (i.e., bacteria, viruses). But in some people, the immune system goes awry and these autoantibodies mistakenly attack healthy cells in a region of the brain known as the basal ganglia. The basal ganglia is responsible for motor control, as well as executive functions and behaviors, and emotions.
When this occurs, it can cause brain inflammation and disrupt how cells and receptors function. This, in turn, leads to the onset of various neuropsychiatric symptoms, including OCD-like behaviors, ADHD, tics, anxiety, and depression.
Only test of its kind
The Autoimmune Brain Panel™, backed by more than two decades of research, is the only test of its kind that can assist clinicians in diagnosing and treating immune-mediated neuropsychiatric disorders.
Identifying an autoimmune process is important, since treatment focuses on eradicating the infection(s) and supporting the immune system, rather than treating solely with psychotropic medications.
Webinar Schedule
About The Webinar
This presentation will review the biological process that occurs when infections trigger an immune dysfunction, impacting the brain and leading to the onset of various neurologic and psychiatric symptoms.
We will describe the signs and symptoms that may help identify whether an individual may be suffering from an autoimmune dysfunction versus a primary psychiatric disorder.
We will also review how the Autoimmune Brain Panel™ can assist in determining whether symptoms may be due to an autoimmune response and highlight several cases of patients who tested positive on the Panel and were successfully treated with a resolution in symptoms.
Webinar Presenter
Craig Shimasaki, PhD, MBA
Craig Shimasaki is President and CEO of Moleculera Biosciences, a neuroimmunology precision medicine company focused on identifying underlying roots of neurologic, psychiatric, and behavioral disorders triggered by an autoimmune response. He is a medical research scientist with over 35 years of translational development experience in biochemical interactions, molecular biology, viral pathogenesis and infection-triggered neuropsychiatric disorders.
Dr. Shimasaki has worked at all stages of research and development from bench to bedside. His research included epitope mapping of HIV proteins, genetic based risk predictors of breast cancer, influenza and RSV diagnostics and therapeutics and pathogenesis of infection triggered neuropsychiatric disorders. As a businessperson, he co-founded multiple companies and led multiple products through the FDA approval process and is a co-inventor on multiple patents.
Dr. Shimasaki started his career at Genentech. He received his BS in Biochemistry from University of California at Davis, his PhD in Molecular Biology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business. He is an Adjunct Professor at the University of Oklahoma where he teaches biotechnology entrepreneurship. His passion is to help translate scientific and medical discoveries into acutely needed products so that more patients can live healthier lives.
